Region-Dependent Role of Cell-Penetrating Peptides in Insulin Absorption Across the Rat Small Intestinal Membrane

AAPS Journal

Volumn 17, Issue 6, 2015, Pages 1427-1437

  Khafagy, El Sayed ^a,b   Iwamae, Ruisha ^a   Kamei, Noriyasu ^a   Takeda Morishita, Mariko ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b SUEZ CANAL UNIVERSITY   (Egypt)

Author keywords

absorption enhancement; cell penetrating peptide; enzymatic degradation; insulin; intestinal membrane

Indexed keywords

CELL PENETRATING PEPTIDE; PENETRATIN; RECOMBINANT HUMAN INSULIN; INSULIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COLON; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DUODENUM; ENZYME DEGRADATION; ILEUM; INSULIN DEGRADATION; INSULIN METABOLISM; INTESTINE EPITHELIUM; INTESTINE LOOP; JEJUNUM; MALE; NONHUMAN; RAT; SMALL INTESTINE; AMINO ACID SEQUENCE; ANIMAL; BLOOD; DRUG EFFECTS; GENETICS; HUMAN; INTESTINE ABSORPTION; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

AMINO ACID SEQUENCE; ANIMALS; CELL-PENETRATING PEPTIDES; HUMANS; INSULIN; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; MOLECULAR SEQUENCE DATA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84945483004     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9804-y     Document Type: Article

References (55)

1. Mustata G, Dinh SM. Approaches to oral drug delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst. 2006;23:111–1135.
2. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006;11:905–10.
3. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med. 2008;358:2545–59.
4. Iyer H, Khedkar A, Verma M. Oral insulin—a review of current status. Diabetes Obes Metab. 2010;12:179–85.
5. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2:289–95.
6. Khafagy ES, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev. 2007;59:1521–46.
7. Lin YH, Sonaje K, Lin KM, Juang JH, Mi FL, Yang HW, et al. Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J Control Release. 2008;132:141–9.
8. Woitiski CB, Veiga F, Ribeiro A, Neufeld R. Design for optimization of nanoparticles integrating biomaterials for orally dosed insulin. Eur J Pharm Biopharm. 2009;73:25–33.
9. Yamagata T, Morishita M, Kavimandan NJ, Nakamura K, Fukuoka Y, Takayama K, et al. Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids. J Control Release. 2006;112:343–9.
10. Sonaje K, Chen YJ, Chen HL, Wey SP, Juang JH, Nguyen HN, et al. Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials. 2010;31:3384–94.
11. Su FY, Lin KJ, Sonaje K, Wey SP, Yen TC, Ho YC, et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials. 2012;33:2801–11.
12. Morishita M, Kamei N, Ehara J, Isowa K, Takayama K. A novel approach using functional peptides for efficient intestinal absorption. J Control Release. 2007;118:177–84.
13. Kamei N, Morishita M, Eda Y, Ida N, Nishio R, Takayama K. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release. 2008;132:21–5.
14. Khafagy ES, Morishita M, Isowa K, Imai J, Takayama K. Effect of cell-penetrating peptides on the nasal absorption of insulin. J Control Release. 2009;133:103–8.
15. Khafagy ES, Morishita M, Kamei N, Eda Y, Ikeno Y, Takayama K. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int J Pharm. 2009;381:49–55.
16. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 1994;269:10444–50.
17. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem. 1996;271:18188–93.
18. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem. 2003;278:31192–201.
19. Kamei N, Morishita M, Takayama K. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J Control Release. 2009;136:179–86.
20. Khafagy ES, Morishita M, Takayama K. The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides. Int J Pharm. 2010;388:209–12.
21. Khafagy ES, Morishita M, Ida N, Nishio R, Isowa K, Takayama K. Structural requirements of penetratin absorption enhancement efficiency for insulin delivery. J Control Release. 2010;143:302–10.
22. Kamei N, Kikuchi S, Takeda-Morishita M, Terasawa Y, Yasuda A, Yamamoto S, et al. Determination of the optimal cell-penetrating peptide sequence for intestinal insulin delivery based on molecular orbital analysis with self-organizing maps. J Pharm Sci. 2013;102:469–79.
23. Khafagy ES, Kamei N, Nielsen EJB, Nishio R, Takeda-Morishita M. One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats. Eur J Pharm Biopharm. 2013;85:736–43.
24. Morishita M, Morishita I, Takayama K, Machida Y, Nagai T. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol Pharm Bull. 1993;16:68–72.
25. Pantzar N, Weström BR, Luts A, Lundin S. Regional small-intestinal permeability in vitro to different-sized dextrans and proteins in the rat. Scand J Gastroenterol. 1993;28:205–11.
26. Asada H, Douen T, Mizokoshi Y, Fujita T, Murakami M, Yamamoto A, et al. Stability of acyl derivatives of insulin in the small intestine: relative importance of insulin association characteristics in aqueous solution. Pharm Res. 1994;11:1115–20.
27. Foged C, Nielsen HM. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv. 2008;5:105–17.
28. Patel LN, Zaro JL, Shen WC. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res. 2007;24:1977–92.
29. Hawiger J. Noninvasive intracellular delivery of functional peptides and proteins. Curr Opin Chem Biol. 1999;3:89–94.
30. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005;57:637–51.
31. Foerg C, Merkle HP. On the biomedical promise of cell penetrating peptides: limits versus prospects. J Pharm Sci. 2008;97:144–62.
32. Khafagy ES, Morishita M. Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev. 2012;64:531–9.
33. Jones AT, Sayers EJ. Cell entry of cell penetrating peptides: tales of tails wagging dogs. J Control Release. 2012;161:582–91.
34. Nielsen EJB, Yoshida S, Kamei N, Iwamae R, Khafagy ES, Olsen J, et al. In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin. J Control Release. 2014;189:19–24.
35. Schilling RJ, Mitra K. Intestinal mucosal transport of insulin. Int J Pharm. 1990;62:53–64.
36. Tozaki H, Odoriba T, Iseki T, Taniguchi T, Fujita T, Murakami M, et al. Use of protease inhibitors to improve calcitonin absorption from the small and large intestine in rats. J Pharm Pharmacol. 1998;50:913–20.
37. Layer P, Jansen JB, Cherian L, Lamers CB, Goebell H. Feedback regulation of human pancreatic secretion. Effects of protease inhibition on duodenal delivery and small intestinal transit of pancreatic enzymes. Gastroenterology. 1990;98:1311–9.
38. Aoki Y, Morishita M, Asai K, Akikusa B, Hosoda S, Takayama K. Region-dependent role of the mucous/glycocalyx layers in insulin permeation across rat small intestinal membrane. Pharm Res. 2005;22:1854–62.
39. Bai JP. Subcellular distribution of proteolytic activities degrading bioactive peptides and analogues in the rat small intestinal and colonic enterocytes. J Pharm Pharmacol. 1994;46:671–5.
40. Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol. 2001;280:G922–9.
41. Ermund A, Schütte A, Johansson ME, Gustafsson JK, Hansson GC. Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer’s patches. Am J Physiol Gastrointest Liver Physiol. 2013;305:G341–7.
42. Tanaka Y, Taki Y, Sakane T, Nadai T, Sezaki H, Yamashita S. Characterization of drug transport through tight-junctional pathway in Caco-2 monolayer: comparison with isolated rat jejunum and colon. Pharm Res. 1995;12:523–8.
43. Winne D, Verheyen W. Diffusion coefficient in native mucus gel of rat small intestine. J Pharm Pharmacol. 1990;42:517–9.
44. Larhed AW, Artursson P, Björk E. The influence of intestinal mucus components on the diffusion of drugs. Pharm Res. 1998;15:66–71.
45. Morishita M, Aoki Y, Sakagami M, Nagai T, Takayama K. In situ ileal absorption of insulin in rats: effects of hyaluronidase pretreatment diminishing the mucous/glycocalyx layers. Pharm Res. 2004;21:309–16.
46. Ward FW, Coates ME. Gastrointestinal pH measurement in rats: influence of the microbial flora, diet and fasting. Lab Anim. 1987;21:216–22.
47. McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol. 2008;60:63–70.
48. Kamei N, Aoyama Y, Khafagy ES, Henmi M, Takeda-Morishita M. Effect of different intestinal conditions on the intermolecular interaction between insulin and cell-penetrating peptide penetratin and on its contribution to stimulation of permeation through intestinal epithelium. Eur J Pharm Biopharm. 2015;94:42–51.
49. Pappenheimer JR, Dahl CE, Karnovsky ML, Maggio JE. Intestinal absorption and excretion of octapeptides composed of D amino acids. Proc Natl Acad Sci U S A. 1994;91:1942–5.
50. Ziegler A, Seelig J. High affinity of the cell-penetrating peptide HIV-1 Tat-PTD for DNA. Biochemistry. 2007;46:8138–45.
51. Lensink MF, Christiaens B, Vandekerckhove J, Prochiantz A, Rosseneu M. Penetratin-membrane association: W48/R52/W56 shield the peptide from the aqueous phase. Biophys J. 2005;88:939–52.
52. Polyansky AA, Volynsky PE, Arseniev AS, Efremov RG. Adaptation of a membrane-active peptide to heterogeneous environment. I. Structural plasticity of the peptide. J Phys Chem B. 2009;113:1107–19.
53. Kamei N, Onuki Y, Takayama K, Takeda-Morishita M. Mechanistic study of the uptake/permeation of cell-penetrating peptides across a caco-2 monolayer and their stimulatory effect on epithelial insulin transport. J Pharm Sci. 2013;102:3998–4008.
54. Kamei N, Morishita M, Ehara J, Takayama K. Permeation characteristics of oligoarginine through intestinal epithelium and its usefulness for intestinal peptide drug delivery. J Control Release. 2008;131:94–9.
55. Ziegler A. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev. 2008;60:580–97.